REGN
Regeneron Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Regeneron Pharmaceuticals has 15 disclosed suppliers and 13 disclosed customers in SEC filings.
Last report4 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputsspot 927.89exp Feb 19ATM strike 920ATM straddle 138.00IV 34%
+13.33%
vs ±3.8% implied · ×3.49
shaded = implied · ▲▼ = realized
SentenceAll of our revenue to date has been generated from the Regeneron Agreement, which is a collaboration and license agreement.
SentenceFor the years ended December 31, 2025 and 2024, our product sales to two distributor customers accounted on a combined basis for 77% and 74% of our total gross product revenue, respectively.
basisREGN FY2025 revenue $14.3B
REGN 10-Kaccession 0000872589-26-000008
SentencePartially offset by: • recognition of $185.0 million of revenue under our collaboration with Regeneron during the year ended December 31, 2024, as we modified the collaboration agreement in June 2024 and provided Regeneron with an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy; • recognition of $65.0 million of milestone revenue under our collaboration with Roche during the year ended December 31, 2024 associated with the dosing of the first patient in the KARDIA-3 Phase 2 clinical trial of zilebesiran; and • revenue recognized under our license agreement with Novartis associated with the achievement of a specified Leqvio commercialization milestone during the year ended December 31, 2024.
SentenceFor example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.
SentenceLicense fee revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million.
SentenceIn May 2026, we entered into a license and collaboration agreement with Regeneron Pharmaceuticals, Inc.
PBLS S-1/Aaccession 0001193125-26-262880PBLS
SentenceWe lease laboratory and office facilities for our corporate headquarters in Tarrytown, New York (the "Facility") under the Third Amended and Restated Lease and Remedies Agreement (the "Lease") with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing & Capital, LLC ("BAL"), as lessor, and the Third Amended and Restated Participation Agreement (the "Participation Agreement") with Bank of America, N.A., as administrative agent, and a syndicate of lenders (collectively with BAL, the "Participants"), as rent assignees.
REGN 10-Kaccession 0001804220-25-000011
SentenceWe lease laboratory and office facilities for our corporate headquarters in Tarrytown, New York (the "Facility") under the Third Amended and Restated Lease and Remedies Agreement (the "Lease") with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing & Capital, LLC ("BAL"), as lessor, and the Third Amended and Restated Participation Agreement (the "Participation Agreement") with Bank of America, N.A., as administrative agent, and a syndicate of lenders (collectively with BAL, the "Participants"), as rent assignees.
REGN 10-Kaccession 0001804220-25-000011
SentenceUnder the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.
REGN 10-Kaccession 0001804220-25-000011
SentenceFor example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.
REGN 10-Kaccession 0001804220-25-000011
SentenceFor example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.
REGN 10-Kaccession 0001804220-25-000011
SentenceAs a result, we rely in part on Sanofi's sales and marketing organization for Dupixent.
REGN 10-Kaccession 0001804220-25-000011
SentenceUnder the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.
REGN 10-Kaccession 0001804220-25-000011
SentenceIn February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in a planned clinical trial of patients with unresectable or metastatic RAS-mutant non-small cell lung cancer.
SentenceIn addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10 % of Regeneron's share of quarterly profits until March 31, 2022, and thereafter at 20 % ), until Regeneron has paid 50 % of the cumulative development costs incurred by the parties to the alliance.
SentenceBayer records net product sales of EYLEA 8 mg and EYLEA outside the United States.
REGN 10-Kaccession 0001804220-25-000011
SentenceRoche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales based on a pre-specified formula.
REGN 10-Kaccession 0001804220-25-000011
Regeneron Pharmaceuticals, Inc.
924.44
+105.67 · +12.91%
post 927.38 +0.32%